Modèles de données sélectionnés

Vous devez être connecté pour sélectionner plusieurs modèles de données, les télécharger ou les analyser.

64 Résultats de recherche.
Pertinence Commentaire Plus récent Moins récent

Framingham Risk Score

- 20/09/2021 - 1 Formulaire, 1 Groupe Item, 7 Eléments de données, 1 Langue
Groupe Item: Score items
The Framingham Risk Score is a sex-specific algorithm used to estimate the 10-year cardiovascular risk of an individual. The Framingham Risk Score was first developed based on data obtained from the Framingham Heart Study, to estimate the 10-year risk of developing coronary heart disease. In order to assess the 10-year cardiovascular disease risk, cerebrovascular events, peripheral artery disease and heart failure were subsequently added as disease outcomes for the 2008 Framingham Risk Score, on top of coronary heart disease. (http://en.wikipedia.org/wiki/Framingham_Risk_Score)

ACTION Registry®-GWTG™ - ACTION Registry

- 18/11/2021 - 1 Formulaire, 8 Groupes Item, 186 Eléments de données, 1 Langue
Groupes Item: Demographics, Admission, Cardiac status on first medical contact, History and Risk Factors, Medications, Procedures and Tests, Reperfusion Strategy, In-Hospital clinical events
The ACTION Registry®–GWTG™ is a risk-adjusted, outcomes-based quality improvement program that focuses exclusively on high-risk STEMI/NSTEMI patients. It helps hospitals apply ACC/AHA clinical guideline recommendations in their facilities and provides invaluable tools to measure care and achieve quality improvement goals. (http://cvquality.acc.org/NCDR-Home/Registries/Hospital-Registries.aspx)

2013 ACCF/AHA Key Data Elements and Definitions for Measuring the Clinical Management and Outcomes of Patients With Acute Coronary Syndromes and Coronary Artery Disease - ACCF/AHA key data elements for ACS

- 18/11/2021 - 1 Formulaire, 6 Groupes Item, 308 Eléments de données, 1 Langue
Groupes Item: Demographics, Time points for STEMI patients, History and Risk Factor Data Elements and Definitions, Clinical Presentation Data Elements and Definitions, Diagnostic Procedure Data Elements and Definitions, Invasive Therapeutic Intervention Data Elements and Definitions
ACCF/AHA key data elements and definitions for measuring the clinical management and outcomes of patients with acute coronary syndromes and coronary artery disease. (http://www.ncbi.nlm.nih.gov/pubmed/23357718)

Acute Coronary Syndrome Common Data Elements - Medication

- 27/09/2021 - 10 Formulaires, 23 Groupes Item, 68 Eléments de données, 1 Langue
Groupes Item: Medication, Aspirin, Anticoagulation, Thrombolytics, Clopidogrel, Low molecular weight heparin, Glycoprotein 2b/3a inhibitors, Unfractionated heparin, Beta-Blocker, Statins, ACE Inhibitors, Angiotensin 2 Receptor Antagonists, Warfarin, Prasugrel, Ticagrelor, Bivalirudin, Fondaparinux, Ticlopidine, Dabigatran, Aldosterone Blocking Agent, Rivaroxaban, Dalteparin, Apixaban
Common Data Elements for Acute Coronary Syndrome

Laboratory

2 Groupes Item 36 Eléments de données

Patient history

1 Groupe Item 8 Eléments de données

ACS-Timepoints

1 Groupe Item 16 Eléments de données

Patient data

2 Groupes Item 27 Eléments de données

Procedures

11 Groupes Item 45 Eléments de données

Diagnosis

8 Groupes Item 29 Eléments de données

Cardiology Audit and Registration Data Standards for Coronary Care Unit [CCU]/Acute Coronary Syndrome [ACS] admissions. - CCU/ACS Data Standards

- 20/09/2021 - 1 Formulaire, 10 Groupes Item, 109 Eléments de données, 1 Langue
Groupes Item: Demographics, Past History relevant to Coronary Artery Disease, Medication: pre hospital, Working Diagnosis, Investigations and Treatment, Medication during hospital stay, Outcome, Medication at discharge, Follow up, Medication at follow up
The main objective of each of the Expert Committees was to produce standardised data sets limited to less than 100 variables. The variables derived had to reflect current treatment guidelines, and also were to be of use for clinical audit, clinical care of patients, service planning and epidemiology. The process involved regular meetings of the Expert Committees, electronic communication between members, and consultation with specialist groups and cardiac societies represented by the European Society of Cardiology. The development of the draft data standards for the three modules was completed in April 2004.

QRISK®2 CVD Score - QRISK Score

- 20/09/2021 - 1 Formulaire, 1 Groupe Item, 14 Eléments de données, 1 Langue
Groupe Item: Score items
QRISK®2 is a well-established cardiovascular disease (CVD) risk score, in use across the NHS since 2009, which is designed to identify people at high risk of developing CVD who need to be recalled and assessed in more detail to reduce their risk of developing CVD. The QRISK®2 score estimates the risk of a person developing CVD over the next 10 years. QRISK®2 has been specifically developed by doctors and academics for use in the UK. The original research underpinning QRISK® was published in July 2007 in the British Medical Journal and in January 2008 in Heart journal. The original research underpinning version 2 of QRISK® (QRISK®2) has been published in the British Medical Journal in June 2008. The research was done using the QResearch anonymised medical research database which consists of the electronic health records of over 10 million patients registered with 550 general practices using the EMIS clinical computer system of whom 2 million contributed to the QResearch database. All medical decisions relating to the QRISK®2 score need to be taken by a patient in consultation with their doctor. The authors, University of Nottingham, ClinRisk and EMIS accept no responsibility for clinical use or misuse of the score. (http://www.qrisk.org/)

ASSIGN Cardiovascular Risk Score Version 1.5 - ASSIGN Score

- 20/09/2021 - 1 Formulaire, 1 Groupe Item, 11 Eléments de données, 1 Langue
Groupe Item: Score items
ASSIGN is a cardiovascular risk score developed in Dundee University, Scotland in 2006. (http://assign-score.com/)

CRUSADE Bleeding Score

- 20/09/2021 - 1 Formulaire, 1 Groupe Item, 8 Eléments de données, 1 Langue
Groupe Item: Score items
The purpose is to help clinicians estimate a patient's baseline risk of in-hospital major bleeding during non-ST-segment elevation myocardial infarction (NSTEMI). (http://www.crusadebleedingscore.org/)

Reynolds Risk Score

- 20/09/2021 - 1 Formulaire, 1 Groupe Item, 8 Eléments de données, 1 Langue
Groupe Item: Score items
If you are healthy and without diabetes, the Reynolds Risk Score is designed to predict your risk of having a future heart attack, stroke, or other major heart disease in the next 10 years. (http://www.reynoldsriskscore.org/)

Excerpt TIMI 46 Acute Coronary Syndrome NCT00402597 - ATLAS ACS TIMI 46

- 17/09/2021 - 1 Formulaire, 66 Groupes Item, 301 Eléments de données, 1 Langue
Groupes Item: Subject Identification, Date of Visit, Demographics, Inclusion/Exclusion Criteria, Index ACS Event, Hospital Discharge for Index Event, Medical History of Special Interest, Vital Signs at Screening, Vital Signs, Physical Examination, Study Medication Review, First Dose of Study Medication, Concomitant Therapy, Aspirin Concomitant Therapy, Thienopyridine, Unfractionated Heparin, Low Molecular Weight Heparin, Parenteral Anticoagulant, Oral Anticoagulant, GP IIb/IIIa Inhibitor, Fibrinolytic, ECG, Unscheduled ECG, DNA Sample, DNA Sample Consent Modification, DNA Sample Replacement, Neurological Exam/Modified Rankin Scale, Seattle Angina Questionnaire, Echocardiogram, Holter, Medication Kit Number, Central Lab Sample Collection, PK/PD Sample Collection, End of Screening / Randomization, End of Treatment / Early Withdrawal, End of Follow-up, CEC Adjudicated Form, Death Adjudication, Myocardial Infarction, Severe Recurrent Ischemia Adjudication, Stroke Adjudication, NON-CNS Systemic Embolization Adjudication, Clinically Significant Bleeding Event Adjudication Form, Stent Thrombosis Adjudication, Canadian Cardiovascular Society Classification of Angina, Events and Procedures Review, Death, Cardiac Ischemic Events, Coronary Revascularization, Coronary Revascularization Prior to Signed Informed Consent, Local Cardiac Biomarker Measurements, Blood Transfusion, Stroke/TIA Events, Hemorrhage, Local Hematology Measurements, Non-CNS Systemic Embolization Events, Other Adverse Events, Local Lab, Health Resource Utilization Review, Emergency Room Visits, Hospitalization, Urgent Care or Physician Office Visit, Skilled Nursing/Rehabilitation Facility, Rehabilitation (Outpatient), Home Care Visits, Investigator Signature
ATLAS ACS-TIMI 46 compared the safety and efficacy of rivaroxaban, an oral direct factor Xa inhibitor, to placebo in patients with acute coronary syndromes. This is an excerpt, empty itemgroups have been added to flag missing items.

Excerpt PLATO Acute coronary Syndrome NCT00391872 - End of Treatment Visit

- 15/04/2021 - 14 Formulaires, 10 Groupes Item, 52 Eléments de données, 1 Langue
Groupes Item: Visit, Clinical Events, Reminder, Procedures, Reminder, Overall Physical Examination, Vital Signs, Weight, Pregnancy Test, Electrocardiogram, NYHA - Heart Failure, EQ-5D Health-Related Quality of Life Questionnaire, Transition Antiplatelet Treatment
Ticagrelor is a new, reversible binding, anti-platelet medication. Anti-platelet medications work to prevent the formation of blood clots. Ticagrelor is being developed as a treatment for patients with acute coronary syndrome (ACS). ACS is a term that is used to describe both heart attacks in progress or the imminent threat of a heart attack. ACS is usually caused by the formation of a blood clot in an artery that partially or totally blocks the blood supply to a portion of the heart muscle. Ticagrelor will be compared with clopidogrel to determine which drug, when either is used in conjunction with aspirin, is better at reducing deaths from vascular causes, future heart attacks and/or strokes in patients with ACS. https://clinicaltrials.gov/ct2/show/NCT00391872

Section Investigational Products

5 Groupes Item 4 Eléments de données

Unscheduled Visit

6 Groupes Item 40 Eléments de données

Visit 4

5 Groupes Item 39 Eléments de données

Visit 2

6 Groupes Item 37 Eléments de données

Section Medication

2 Groupes Item 2 Eléments de données

Follow-up Visit

4 Groupes Item 33 Eléments de données

STEMI-Register Münster - STEMI-Register Münster Klinischer Verlauf

- 14/04/2021 - 1 Formulaire, 8 Groupes Item, 83 Eléments de données, 2 Langues
Groupes Item: Demografisch, Patient history, Medication: pre hospital, Risk Factors, Admission examination, Investigations and Treatment, Outcome, Medication at discharge
STEMI-Register Münster

Aide

Do you need help on how to use the search function? Please watch the corresponding tutorial video for more details and learn how to use the search function most efficiently.

Watch Tutorial